<SEC-DOCUMENT>0001279569-18-001246.txt : 20180605
<SEC-HEADER>0001279569-18-001246.hdr.sgml : 20180605
<ACCEPTANCE-DATETIME>20180605133651
ACCESSION NUMBER:		0001279569-18-001246
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180605
FILED AS OF DATE:		20180605
DATE AS OF CHANGE:		20180605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38512
		FILM NUMBER:		18880649

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>oncolyticsform6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 14pt/normal Times New Roman,serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 12pt/normal Times New Roman,serif; margin: 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 18pt/normal Times New Roman,serif; margin: 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman,serif; margin: 0; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 12pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman,serif; margin: 0; text-align: center"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16</B></P>

<P STYLE="font: 12pt/normal Times New Roman,serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center">For the month of       June 2018</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center">Commission File Number 000-31062</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 24pt/normal Times New Roman,serif; margin: 0; text-align: center"><B>Oncolytics Biotech Inc.</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 70%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 24pt/normal Times New Roman,serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center"><I>(Translation of registrant&rsquo;s name into
English)</I></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center"><B>Suite&nbsp;210, 1167 Kensington Crescent NW</B></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center"><B>Calgary, Alberta, Canada T2N 1X7</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 70%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center"><B><I>(Address
of principal executive offices)</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">Indicate by check mark whether the registrant files or will file
annual reports under cover Form&nbsp;20-F or Form&nbsp;40-F.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 60%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 49%; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font: 10pt Times New Roman,serif">Form&nbsp;20-F&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&thorn;</FONT></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font: 10pt Times New Roman,serif">Form&nbsp;40-F&nbsp;&nbsp;&nbsp;&#9744;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K
in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits
the submission in paper of a Form&nbsp;6-K if submitted solely to provide an attached annual report to security holders.</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K
in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits
the submission in paper of a Form&nbsp;6-K if submitted to furnish a report or other document that the registrant foreign private
issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant&rsquo;s &ldquo;home country&rdquo;), or under the rules of the home country exchange on which the registrant&rsquo;s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed
to the registrant&rsquo;s security holders, and, if discussing a material event, has already been the subject of a Form&nbsp;6-K
submission or other Commission filing on EDGAR.</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under
the Securities Exchange Act of 1934.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 60%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 49%; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font: 10pt Times New Roman,serif">Yes&nbsp;&nbsp;&nbsp;&#9744;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%; font-family: Calibri,sans-serif"></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%; font-family: Wingdings"><FONT STYLE="font: 10pt Times New Roman,serif">No
<FONT STYLE="font-family: Wingdings">&thorn;</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number assigned
to the registrant in connection with Rule&nbsp;12g3-2(b):&nbsp;&nbsp;&nbsp;82&nbsp;-&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid"><P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>EXHIBIT</B></FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NUMBER</B></FONT></P></TD>
    <TD STYLE="width: 2%; line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 90%; line-height: 115%; font-family: Calibri,sans-serif; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DESCRIPTION</B></FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex991.htm">99.1</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex991.htm">News Release Dated June 4, 2018 - Oncolytics Biotech&reg; Announces Poster Presentation Demonstrating the Ability of REOLYSIN&reg; to Promote and redict Response
to Checkpoint Inhibitors at ASCO 2018 Annual Meeting</A></FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center; line-height: 115%; font-family: Calibri,sans-serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex991.htm">99.1</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif"><A HREF="ex991.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">News
Release Dated June 5, 2018 - Oncolytics Biotech&reg; Closes USD $8.9 Million Public Offering of Common Shares</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 11pt">
<TR>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0"><B>Oncolytics Biotech Inc.</B></P>
        <P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">(Registrant)</P></TD></TR>
<TR>
    <TD STYLE="width: 50%; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 5%; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 45%; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font: 10pt Times New Roman,serif">&nbsp;Date:&nbsp;&nbsp;
          June 5, 2018</FONT></TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font: 10pt Times New Roman,serif">By:</FONT></TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman,serif">/s/&nbsp;&nbsp;Kirk Look</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font: 10pt Times New Roman,serif">Kirk Look</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font: 10pt Times New Roman,serif">Chief Financial Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED JUNE 4, 2018
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>



<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><IMG SRC="image_001.jpg" ALT=""><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Oncolytics Biotech<SUP>&reg;</SUP> Announces
Poster Presentation Demonstrating the Ability of REOLYSIN<SUP>&reg;</SUP> to Promote and Predict Response to Checkpoint Inhibitors</B><BR>
<B>at ASCO 2018 Annual Meeting</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>CALGARY, AB and SAN DIEGO, CA, June 4, 2018
- </B>Oncolytics Biotech<SUP>&reg;</SUP> Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing REOLYSIN<SUP>&reg;</SUP> (pelareorep),
an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a key poster presentation at the American
Society of Clinical Oncology (ASCO) 2018 Annual Meeting. The meeting takes place from June 1 - 5, 2018 at McCormick Place, Chicago,
IL.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;These results demonstrate that pelareorep
promotes the expression of gene signatures predictive of a response to immunotherapy in breast cancer and hepatocellular carcinoma.&rdquo;
said Matt Coffey, President and CEO of Oncolytics Biotech. &ldquo;The tumor inflammation promoting effects in breast cancer models
provide a compelling explanation for the significant overall survival benefit in hormone receptor positive metastatic breast cancer
patients in our phase 2, IND 213, study and we believe this will continue to drive interest in our breast cancer program.&rdquo;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Highlights of the
poster include:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><FONT STYLE="font-size: 11pt">Pelareorep promotes expression of gene signatures that are predictive of response to checkpoint
inhibitors in select cell lines</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><FONT STYLE="font-size: 11pt">HCC &#9;- hepatocellular carcinoma</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><FONT STYLE="font-size: 11pt">HR+ BC &#9;- hormone receptor positive breast cancer</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><FONT STYLE="font-size: 11pt">Pronounced tumor inflammatory effects of pelareorep in HR+ BC cells may explain the prominent
increase in overall survival in a previous phase 2 randomized clinical study in HR+ mBC patients treated with pelareorep and may
render this large breast cancer population susceptible to conventional immunotherapy regimes</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><FONT STYLE="font-size: 11pt">Results warrant further investigation of pelareorep in combination with checkpoint inhibitors</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%"><FONT STYLE="font-size: 11pt"><B>Presenter &amp; Lead Author:</B></FONT></TD>
    <TD STYLE="width: 71%"><FONT STYLE="font-size: 11pt">Grey A. Wilkinson PhD, Oncolytics Scientist, Translational Medicine</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 11pt"><B>Presentation Title:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 11pt">Pelareorep to promote the expression of a IFN-gamma-related gene signature that predicts response to checkpoint blockade therapy</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 11pt"><B>Session Title:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 11pt">Developmental Therapeutics - Immunotherapy</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 11pt"><B>Location:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 11pt">McCormick Place: Hall A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 11pt"><B>Abstract&nbsp;number:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 11pt">3089</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 11pt"><B>Poster Board #:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 11pt">303</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 11pt"><B>Date/Time:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 11pt">6/4/2018; 8:00 AM-11:30 AM</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The complete poster can be found online on
the company website at https://www.oncolyticsbiotech.com/technology/posters-publications.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About REOLYSIN/Pelareorep&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">REOLYSIN, also known as pelareorep, is a non-pathogenic,
proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment
of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype
through innate and adaptive immune responses to treat a variety of cancers.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Oncolytics Biotech Inc.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Oncolytics is a biotechnology company developing
REOLYSIN<SUP>&reg;</SUP>, also known as pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective
tumor lysis and promotes an inflamed tumor phenotype - turning &quot;cold&quot; tumors &quot;hot&quot; - through innate and adaptive
immune responses to treat a variety of cancers. Oncolytics' clinical development program emphasizes three pillars: chemotherapy
combinations to trigger selective tumor lysis and immuno-therapy and immune modulator (IMiD) combinations to produce innate and
adaptive immune responses. Oncolytics is currently planning its first registration study in metastatic breast cancer, as well as
studies in combination with checkpoint inhibitors and targeted and IMiD therapies in solid and hematological malignancies. For
further information, please visit: www.oncolyticsbiotech.com.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This press release contains forward-looking
statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information
under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred
to herein as &ldquo;forward-looking statements&rdquo;). Forward-looking statements, including the Company's belief as to the potential
and mode of action of REOLYSIN, also known as pelareorep, as a cancer therapeutic; and other statements related to anticipated
developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as
a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize
pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process
and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements.
Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update
these forward-looking statements, except as required by applicable laws.</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Company Contact</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Michael Moore</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Vice President, Investor Relations &amp; Corporate Communications</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">858-886-7813</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">mmoore@oncolytics.ca</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Investor Relations</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Robert Uhl</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Westwicke Partners</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">858-356-5932<BR>
        robert.uhl@westwicke.com</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="width: 48%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Media Contact</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Jason Spark</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Canale Communications&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
        619-849-6005</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">jason@canalecomm.com</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex992.htm
<DESCRIPTION>NEWS RELEASE DATED JUNE 5, 2018
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.2</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>



<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><IMG SRC="image_001.jpg" ALT=""><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: right"></P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Oncolytics Biotech<SUP>&reg;</SUP> Closes
USD $8.9 Million Public Offering of Common Shares</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>CALGARY, AB and SAN DIEGO CA, June 5, 2018
- </B>Oncolytics Biotech<SUP>&reg;</SUP> Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing REOLYSIN<SUP>&reg;</SUP> (pelareorep),
an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced the closing of its previously announced
underwritten public offering of 1,532,278 common shares, including 160,065 common shares pursuant to the exercise of the underwriters&rsquo;
option to purchase additional common shares (the &ldquo;Offering&rdquo;). The shares were sold at a public offering price of USD
$5.83 per share. The gross offering proceeds to the Company from this Offering are approximately USD $8.9 million, before deducting
underwriting discounts and commissions and other estimated offering expenses.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ladenburg Thalmann &amp; Co. Inc., (the &ldquo;Underwriter&rdquo;)
a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE American: LTS), acted as the sole book-running manager in connection
with the Offering.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Offering was made pursuant to a U.S. registration
statement on Form F-10, declared effective by the United States Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on May
7, 2018 (the &ldquo;Registration Statement&rdquo;), and the Company&rsquo;s existing Canadian short form base shelf prospectus
(the &ldquo;Base Shelf Prospectus&rdquo;) dated May 4, 2018. The prospectus supplements relating to the Offering (together with
the Base Shelf Prospectus and the Registration Statement, the &ldquo;Offering Documents&rdquo;) have been filed with the Alberta
Securities Commission in Canada, and with the SEC in the United States. No common shares will be offered or sold to Canadian purchasers.
The Offering Documents will contain important detailed information about the securities being offered. Before you invest, you should
read the Offering Documents and the other documents the Company has filed with the SEC for more complete information about the
Company and the Offering. Copies of the Offering Documents are available for free by visiting the Company&rsquo;s profiles on the
SEDAR website maintained by the Canadian Securities Administrators at&nbsp;www.sedar.com&nbsp;or the SEC&rsquo;s website at&nbsp;www.sec.gov.
Alternatively, copies of the prospectus supplements are available upon request by contacting Ladenburg Thalmann &amp; Co. Inc.,
Attn: Prospectus Department, 277 Park Avenue, 26th Floor, New York, New York 10172, by calling (212) 409-2000.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This press release does not constitute an offer
to sell or the solicitation of an offer to buy securities, nor will there be any sale of the securities in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of
any such jurisdiction.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Oncolytics Biotech Inc.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Oncolytics is a biotechnology company developing
REOLYSIN, also known as pelareorep, an intravenously delivered immuno-oncolytic virus. Oncolytics is currently planning its first
registration study in metastatic breast cancer, as well as studies in combination with checkpoint inhibitors and targeted and IMiD
therapies in solid and hematological malignancies.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This press release contains forward-looking
statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information
under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred
to herein as &ldquo;forward-looking statements&rdquo;). Forward-looking statements, including the Company's belief as to the potential
and mode of action of REOLYSIN, also known as pelareorep, as a cancer therapeutic; and other statements related to anticipated
developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as
a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize
pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process
and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements.
Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update
these forward-looking statements, except as required by applicable laws.</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Company Contact</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Michael Moore</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Vice President, Investor Relations &amp; Corporate Communications</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">858-886-7813</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">mmoore@oncolytics.ca</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Investor Relations</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Robert Uhl</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Westwicke Partners</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">858-356-5932<BR>
        robert.uhl@westwicke.com</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="width: 48%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Media Contact</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Jason Spark</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Canale Communications&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
        619-849-6005</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">jason@canalecomm.com</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !8 -4# 2(  A$! Q$!_\0
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M^*?[,/[1O[5/_!%/]K[X??L!?MW?%#7/C7^PM\?M>F\*?L/?M>>,WN=2\5^
M/$\NH6<.C_!#XU^(A;QQ(DO]I1Z98:CJ4TEAH:+I&HZ%=V'@*?7=&^&G]C+!
M6!# $8.00#_.OR%_X+0_L6>%OVV?V!/VAO@]JMCO\36W@G5_B)\*M5@11?\
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MP[X5\3_VQI.JEO".K_\ "57G]LKI1TW63]GMOL6IVO[W?V7[8G['?P"_;N^
MGC#]F_\ :2\&#QI\,_&)TZ[GMK;4K_0]<T+7=$O$U#0/%/A?Q!I<L.HZ'XBT
M.^C6XLKZV<QSQ/<Z9J5O?Z/J&HZ?= 'TM#)%'%%'Y@.U5C!&3DJ%'.T$+C<"
MV<!1G. K8_);_@IA^P%\9_VG?B/^R=^U7^R5\<O#?P,_;(_8BUCXJZM\%]1^
M)?A(^./@SXXT#XT^&M(\(?$SP!\3-&M0VNZ5IOB/0-%@TR'Q9X7CNM?T2RO=
M8;3=/DU6;2M8T#QKP-_P19^(_A35? VA:W_P5Q_X*;^-?@;\-/$?A;Q'X/\
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M?>)]#\&:#\'93"TQ^(5M?[M#32)I?[-O&_B:V\%^"_%_C&]MY[NS\)^%]?\
M$UW:6WEBYN;;0=)N]4GM[?SF6+SYHK5XXO-98_,9=[!<FOD>U_X*!_LJ6TFO
MZ?K/CZ_T;Q'X0\+Z!XH\3Z$_@3XB:E=6<>OQ?"\1:#H5]I'A2_TOQ]XLTR?X
MV?"*RU[PI\/KWQ3XBT:?XE>!Y-5TNTM_$^BS78!^0^@^,?VMI?\ @G3_ ,%N
M-5_9GU+XA^(_VCO#_P"WW_P4+T3X-+H<NH^(O'NE:1IOQ!T&U?3OA;9W<L]V
M/$'A_P 'S:_/\-]%T0!K;Q)%I,.BVGVN2WBD\P_8=\1?LR']O;]D_3?^"3OQ
M@^/WQ>^&FJ>!?C7#_P %++7X@_%+]HOXL>$/#VBVWP[^W_![Q)\4&^/VJZOI
MGP\_:CU'X\0Z;I4>@>"_[ \62^%[CXBV>L^%],\+6:R6W[B^+?\ @H1^RSX7
M\,Z1XE7Q=XDUF3Q9\/?B7\0O!6DZ3\,OBA-J'BF/X3Z/XYUCQOX*B#^#X[;1
M?BIHB_#3QW9WWPD\33:-\2[;4O"7B2QE\)K>:'JL-I3N?V^?@#;>';.^L+OQ
M-<>,[[P'X%^(:^![_P &^,/#&I06/CQ?!-S!X?O-8\5>'M$\,0?$#1-"\?>&
M?$OB3X<3ZE'\1=&\*:IIWB74O"]IHFHV%_, ?E?\.?V'?@!H7_!=#XD^']/T
MWXN1>%_ ?[%WP"_:U\)Z%>?M)?M*ZKX:T[]HCQ7^U)\?]*\1^,I=#U3XM7FB
MZG:7^C^$?#-E)X"U>SO_ (>0V-@D%MX3AAN+E9OCOXM>-_A!_P /^?CIX<^.
M?Q2^#&CC1?BO^P9_PJ/PI\7/VF_VM/A;XW.I:G\*_!%Y-:_ WX6?!S6++X,_
M$*^U7Q@VEG5-)^+=O_8NI:U<6MAJ45SIFH:DDG]1WA_]H;X(^*+?Q=?Z'X_T
M.\M/ 7@K3OB#XZU1WNK+2_"7A34M0\=Z4NH^(]0OX+2QTJ?3M3^&/CNT\0Z)
M>R0ZYX8F\/77_"1Z5I2W5BUY\W>'_P#@H9\$]:^#?P'^)L^C_$/1]7_:!\9:
M5X"\/_#.Z\%Z]J7C;PAXLA^,OA3X$?$#3_B,OABP\0:+X%T[X7?$KQ5I_AKQ
MAXG\3:GI7A>/6+K2=%L=8N-9\2>';'40#\A/V]O$7[-*_P#!1?XL:1_P5F^*
MOQC^%/[)%G\ ?@E)^P?)H?Q6_:*^"WP0\3_$B[OOB.?VDKZ\\3_L_>(/#'_"
M3?M :!?1?#FT\,^'/%.JWFL6/@Z[BO\ P[H-V;M+F'ZH_;)\1_M :/\ MK?\
M$D]'_8VO_!&OWFO_  A_;;N+'2?CSX\^*VB_#KQ5X4T?X;_LZOHVK^,]4\-Z
M'XO\8:YXCL=+O9+O0;KQ!I%W?G4;V_GU"]M[J\NGE^^M>_X*!?L@^&K;Q#=>
M(_B1J>CMX5\<:U\/?%%OJ/PR^+=KJ&@Z[X;T'4?%.OZQJNF2^!_[0LOAUHWA
MC2-:\3ZE\6Y;0?"FT\.Z%KVOS>,ETK0=7O+*U\.?VU_A+X[US7M.*>(O"5KX
M:^)7Q2^%5S>^-O#7B?PT^I>(_AG\2OA3\)Y-0\.Q:OX?LD\0>%-?\6?&'PG:
MV7B[3;RZT&W^WPFZOF(U.31P#Y%_X(R^(OB_XC^'O[<\WQUU#3+WXDZ7_P %
M.?VQ-#UZU\.:_P"*?$O@K0IM-UWPJLGAWX?:IXQL],UYO ND74MU!X;M[S2]
M+>*R96.G6AD,0]6^-FNZ];?\%:/^"?\ X=L]7U>#PYJO[(?_  43U/7-$M[^
M^BT34-3TCQO^PM#X?U#5-,BF6PN[_38=3UV'2+R[@DN+2+4-6BLWC6XN@WJ?
MQ)_;[_9\\$^'/&NJ^&_$DGC;Q+X6^%/C#XO6'AJRTGQ/H]AXTT7P9X-U;XBZ
MAX=\-^.]6\.?\(-/X[U+X?Z!JOCKP]X'_MO_ (2C6/ T47Q!M]'/@&Y3Q0&_
MLG_MO^#_ -J[X@?'/X=:#X%\<^#?%'[.NL0^%_B'_P )7I\-MI4OB6;XG_';
MX;"R\+:@K1R>(-*N+3X))X]TW7X;6&PO_"'Q#\&$_9=?'B/1-$ /Y??VL_BI
M^WK\,_A3_P ' /Q+^'&M?$/XR?LXW_[1G[1_[/FN?#7PQ>:RWQ3_ &7/$'_#
M,'P'\4^"/VE/A'JB:A'<'X5V^K^.=0T#XZ>%-,DM;KP=IMMH'Q5\*(J:/X]@
MU+]%?^"C.O?LVP?MZ:/I7_!4+XI?%_X5_L11_LJ^!M0_9BO?#?Q0^/7P@^ 7
MB;]HVZ^(7Q%M_CA'\2/&OP*U_P ,:C??&G0O!UM\(9OA1X;\1ZV=)/AG4?%5
M]X=LKC7YM1*_TGM#$Q8M&K%AAMPR&'<%3D'(X.1R %.0  PVEN1M,0QE3U89
M*?=)(.3MP,9)QM7'W5P ?.?P'^+WP*U6'PC\#?A;XZO?$>I^#_V?_@]\3-%T
MKQ#?^-=<\83?!+QQ;ZUX:^%OC?Q'XD\<12Z_K=]XH;P-K\%Y>^)=5O/&=UJ6
ME7U_XHCCOKP37'TI4:1)']Q<<8)R23C^\S$ECSU))]ZDH **** "BBB@ HHH
MH **** "BBB@ HHHH **** ,7Q)H&F>*_#NO>%M:A>XT?Q+HNJ:!JT$<LEO)
M-IFLV,^G7\*3PLDT+R6MS*BRQ.DD;,'1E901\IW'[!_[.-UJ-OJL_A75FO+7
M5(M9A=?%/B%$&H0W?[.]ZDK1#4=C1B;]ECX,YA(,3)H.J(RD>(]9^U_8U% '
MP)/_ ,$S_P!DJY^(]A\5)_!.LR>++"]^)&I"?_A,?$PMKJ^^*NO?M#>(O%=Q
M<Q?VF9MKWW[57QX33K*WN;?3;&W\<?+927/A[PO<Z+M:9_P3Q_9BT[Q+J_C%
M_"%WJ?BOQ#X)\#^!?$/B75]2?4/$6M:=\/=,\#Z%X>U.[\131'7H=:.A?#CP
M;H^HSV&I6=A?66D.&TZ.?4]8FU#[AHH ^0?#W[&/PCLO ?[2WPR\0Z3;:]X'
M_:J^)?Q(^('Q8\,V]O>Z)HNN6GQ.CT^P\6>$Y[6/5KV>31/%6E6$_P#PG$,5
M[;V?BW6?$WC?69-.TS_A*+NPBS8OV!/V;-+N_"LOA#PC>_#C2_!_CL_$'2O"
MOPTUO5/ O@PZK+XF^%7CF]TNX\)>';FQT$^&M5\?_!7X=^/-7T2WL+>VU/Q7
MIVN:E=M*OC3QC;ZY]H44 ?F)JO\ P2B_9IGGL[71+CXA>&/#%[?:\/''A_0/
M&_B?2YO&OA?6_A[XI^&!\#76OZ3J^G:OIOAQ/!OC+7-$OYK>:;Q!K%I/'>WV
MN'Q-:V7B2U^C+O\ 8M^ ]]9?$32[O1-=FTGXFZ-\9/#VO:6/%>OVUGIVB_'I
M/A_+\2K'PJ+._MI_#!U35_AIX9\1Z9>Z3/;ZEX;U];^_\/7NF"Z6&'ZOHH ^
M4?!7[%/[.OP]^+=A\;/"7@'3M,\>:9X \/\ PWL=09([]+30/#'AK2_!.BS6
MCZC'=ZA9:I:^!]&T_P &R7=G?V\=[X?B:VU"WNYY9+EOJI(88V9XXHXV< .R
M(JLP5G90Q4 L TDC $D!G<CEF)DHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
+ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
